降脂调压颗粒治疗原发性高血压病及其血管内皮功能保护作用的临床研究

目的 :探讨降脂调压颗粒对原发性高血压病患者的降压疗效 ,及其对血管内皮功能的保护作用。方法 :5 9例原发性高血压病患者 ,分别给予降脂调压颗粒 (30例 )及对照药金甲益心酮 (2 9例 ) ,观察治疗前后临床症状、体征、血压、心率等变化情况 ;并采用放射免疫分析法测定治疗前后内皮素 (ET)、降钙素基因相关肽 (CGRP)含量。结果 :降脂调压颗粒降压总有效率为 90 0 % ,显效率为 36 7% ;症状改善总有效率为 90 0 % ,显效率为 6 0 0 % ,症状改善明显优于对照组 (P <0 0 5 )。降脂调压颗粒还可降低血浆ET水平及ET/CGRP比值 (P <0 0 5 ,P <0 0 1) ,升高血浆CGRP水平 (P <0 0 5 )。结论 :降脂调压颗粒具有较好的临床降压疗效 ,同时可以保护高血压状态下的血管内皮功能

英文摘要:

To observe the therapeutic effect of Jiangzhi Tiaoya Granule (JZTYG) in treating essential hypertension and its protection on function of vascular endothelial cells (VEC). Methods: Fifty nine patients of essential hypertension divided into two groups were treated with JZTYG (the treated group) and Jinjia Yixintong (the control group) respectively. The changes of symptoms, signs, blood pressure, heart rate were observed and the levels of endothelin (ET), calcitonin gene related peptide (CGRP) content were determined by radioimmunoassay (RIA). Results: The total effective rates of JZTYG in lowering blood pressure and improving symptoms were both 90.0%, markedly effective rate in lowering blood pressure and improving symptoms was 36.7% and 60.0% respectively. The symptom improved in the treated group was better than that in the control group (P<0 05). It also could reduce the plasma ET level (P<0 05) and ET/CGRP ratio (P<0 01), and increase the CGRP level (P<0 05). Conclusion: JZTYG has a promising clinical therapeutic effect in treating essential hypertension and is able to protect the VEC function.

关闭